On 14 August, the World Health Organization (WHO) declared that the monkeypox outbreak constituted a ‘public health emergency of international concern’, marking the second time since July 2022 that WHO has issued the highest level of alert for a monkeypox outbreak. Currently, the monkeypox epidemic has spread from Africa to Europe and Asia, and confirmed patients infected with the monkeypox virus have been found in Sweden and Pakistan. According to the latest data from the African Centre for Disease Control and Prevention (CDC), this year the African Union has 12 member States with monkeypox outbreaks, with a total of 18,737 reported cases of monkeypox, including 3,101 confirmed cases, 15,636 suspected cases and 541 deaths, representing a mortality rate of 2.89 per cent. What is monkeypox? （Monkeypox ,MPX) is a viral zoonosis caused by the monkey pox virus, which can be transmitted from animals to humans or between humans, with fever, rash, and swollen lymph nodes as representative symptoms. Monkeypox virus mainly invades the human body through mucous membranes and broken skin, and the sources of infection include monkeypox cases and infected rodents, monkeys and apes and other non-human primates. After infection with monkeypox virus, the incubation period is 5~21 days, mostly 6~13 days. The population is generally susceptible to the monkeypox virus, although there is a degree of cross-protection against the monkeypox virus due to the similar genetic and antigenic characteristics of the same species of orthopoxviruses that have been vaccinated against smallpox. At this stage, the main mode of transmission of monkeypox is through sexual contact among men who have sex with men, and the risk of monkeypox virus infection in the general population is currently low. What's different about this round of Monkey Pox? Since the beginning of the year, the main strain of monkeypox virus, the ‘branch II strain’, has caused a major global outbreak. Worryingly, the proportion of recent cases of the ‘branch I strain’, which is more severe and lethal and has been diagnosed outside the African continent, is increasing. Meanwhile, a new, more lethal and more transmissible variant of ‘branch Ib’ has been spreading in the Democratic Republic of the Congo since last September. The striking feature of this outbreak is that women and children under 15 years of age are the most affected. Data show that more than 70 percent of all reported infections are among patients under 15 years of age, and among deaths, the figure is as high as 85 percent. Particularly noteworthy is the fact that the mortality rate among children is four times higher than among adults. What is the risk of spreading monkeypox? The risk of transnational transmission of monkeypox virus may increase due to the peak travelling season and frequent international contacts. However, the monkeypox virus is mainly transmitted through prolonged close contact, such as sexual intercourse, skin-to-skin contact and...

On October 8, 2021, the novel coronavirus (COVID-19) neutralizing antibody (double antigen sandwich) detection reagent (colloidal gold method) independently developed by Anhui Deepblue Medical successfully obtained the CE1434 certificate, which meets the relevant EU requirements and market standards. Entry qualification. CE 1434 self-test certification is not only difficult, long-term, and strict, but also a test of comprehensive strength. In July 2021, DeepBlue Medical's novel coronavirus (COVID-19) antigen detection reagent obtained the CE1434 certificate, and the new coronavirus (COVID-19) neutralizing antibody (double-antigen sandwich) detection reagent obtained the CE1434 certificate. The strong recognition of the research and development technology of viral in vitro diagnostic reagents has far-reaching significance for the development of the international market and brand expansion. The novel coronavirus (COVID-19) neutralizing antibody (double-antigen sandwich) detection reagent independently developed by Anhui Deepblue Medical has obtained the CE1434 certificate, which can not only be freely sold in the 31 EU member states, but also bring more convenience to the global anti-epidemic. Check resources. The blessing of the CE1434 certificate also reflects the European market's recognition of the performance and user experience of DeepBlue Medical products, and it is also a high affirmation of the comprehensive strength of DeepBlue Medical. At present, most countries and regions in the world have gradually shifted from nucleic acid testing during the outbreak to neutralizing antibody testing to assess whether immunity is protected. The Deepblue Medical Novel Coronavirus (COVID-19) Neutralizing Antibody (Double Antigen Sandwich) Detection Reagent can simply, quickly and effectively reflect the presence and level of neutralizing antibodies after vaccination, and play a guiding role in the need for booster vaccination. In the future, Deepblue Medical will continue to adhere to the vision of "based on the health industry, give full play to the advantages of science and technology, and build a health industry aircraft carrier", strive to develop better products, and contribute to the global epidemic prevention and control and the evaluation of the immune effect of vaccines!

On December 1st, 2022, DEEPBLUE Medical COVID-19 Antigen Self-test Saliva Reagent completed the registration of CTDA in the UK, and was approved to be listed in the UK as an antigen saliva self-test product. The certificate is valid for 5 years. DEEPBLUE Medical is the first enterprise in China to obtain saliva self-test CTDA. With rich industry experience and professional independent research and development ability, DEEPBLUE Medical actively expands overseas registration while deeply studying international industry regulations, product certification regulations and commercial systems of various countries. At present, a series of products independently developed and produced by DEEPBLUE Medical have successively participated in the bidding activities of governments all over the world, and have been listed and sold in hospitals, supermarkets and pharmacies in several overseas countries, thus establishing a stable and reliable regional network, and making more DEEPBLUE Medical products go global. The successful achievement of CTDA certification of saliva product, an antigen self-test reagent in COVID-19, will help DEEPBLUE Medical to further expand overseas product sales channels and enhance the influence of its own brand, creating favorable conditions and laying a solid foundation for more independent brand products to enter the international market in the future. DEEPBLUE Medical will take this certification as an opportunity to further improve the quality of professional products, enhance the comprehensive strength of DEEPBLUE Medical with high-level international technical means, and provide strong support for the development of POCT industry.

DEEPBLUE COVID-19 Antigen Test can detect Omicron variants  Evaluated by UCK Poland Screenshot of the evaluation report Since the launch of the COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold), we have closely followed market changes and needs, and have always paid attention to the feedback of users and distributors after the product has been launched, and continuouslyvalidate our test with new variants. Recently we have completed the Clinical Evaluation on UCK Poland and the results indicates DEEPBLUE Antigen test is able to detect Omicron variants and the sensitivity is very high. Screenshot of the evaluation report

The four products of Monkeypox Virus Antigen Test Kit (Colloidal Gold), Monkeypox Virus IgG/IgM Antibody Test kit (Colloidal Gold), Monkeypox Virus Nucleic Acid Test Kit (Isothermal Amplification- Real-time Fluorescence) and Monkeypox Virus Nucleic Acid Test Kit (PCR-Fluorescent Probe) self-developed by DEEPBLUE Medical have passed the registration in Germany and UK. DEEPBLUE Medical, established in February 2010, is a national high-tech enterprise focusing on the R&D, production and marketing of in vitro diagnostic reagentsIt has been awarded the honors of Anhui Export Brand Demonstration Enterprise, Anhui Trademark Brand Demonstration Enterprise, Hefei Brand Cultivation Enterprise, Hefei Specialized and New Enterprise, Hefei Enterprise Technology Center, Hefei Harmonious Labor Relations Demonstration Enterprise, and High-tech Zone Three-Eight Red Flag Collective, etc. DEEPBLUE Medical has obtained CE 0123, CE 1434 and UK MHRA certifications for many products; 118 registrations have been obtained in many countries; virus test products have passed clinical validation in Germany PEI, Spain, Poland UCK, Denmark, the United States and other countries, with product footprints in Europe, North America, South America, the Middle East, Southeast Asia and nearly 100 countries around the world. DEEPBLUE Medical will continue to pay attention to international public health events, uphold the mission of "customer satisfaction is our highest honor, employee satisfaction is our eternal goal, shareholder satisfaction is our greatest responsibility", is committed to play the role of rapid diagnostic products in disease surveillance, health warning, and constantly increase investment in research and develop more directional test products to contribute to the promotion of high-quality development of the IVD industry. Popular Science Monkeypox is a zoonotic virulent disease caused by monkeypox virus (MPXV). It is a double-stranded DNA virus belonging to the genus orthopoxvirus of the family Poxviridae, along with smallpox virus, vaccinia virus and cowpox virus. In the past 4 months, the monkeypox epidemic has spread to 105 countries and regions. WHO data show that as of September 19, 2022, countries have reported 61,753 laboratory-confirmed cases and 533 suspected cases, including 23 deaths.

The novel coronavirus antigen detection kit independently developed by Anhui Deep Blue Medical Technology Co., Ltd. passed the 3B stage test of the British government in 2020, and successfully obtained the British MHRA registration certificate. Good news came from Germany in 2021. At the beginning of March, the novel coronavirus antigen detection kit passed the evaluation of the German laboratory PEI. German TV stations simultaneously explained the steps of using the dark blue antigen detection kit to the public in detail, no laboratory equipment or professional Laboratory personnel or medical personnel operate. After obtaining special permission from Germany, the public can take samples and test at home. The results will be obtained within 15-20 minutes, and the test results will be used to determine whether they are infected with the new coronavirus. The Deepblue Novel Coronavirus Antigen Detection Kit is simple to operate, fast to detect, and easy to sample. Both front nasal swabs and saliva can be detected. Report link: https://v.qq.com/x/page/x3233f39lbk.html

On the afternoon of March 17, Yu Aihua, Member of the Standing Committee of the Provincial Party Committee and Secretary of the Municipal Party Committee, went to Hefei High-tech Zone to preach the spirit of the National Two Sessions, investigate the biopharmaceutical industry and grass-roots party building work, and coordinate on-site to help enterprises solve problems. Wu Lihua, director of the Provincial Drug Administration, and city leaders Shan Hu and Song Daojun attended the ceremony. Ms. Chen Fengling, general manager of DEEPBLUE Medical, and the heads of relevant departments warmly received and accompanied the visit and research.     Secretary Yu expressed strong interest in the New Coronavirus series testing products of different languages and specifications displayed by DEEPBUE Medical. Ms. Chen Fengling, general manager of DEEPBLUE Medical, introduced the self-developed New Coronavirus antigen detection reagents to Secretary Yu and his party by taking the product types and usage methods as the starting point. Secretary Yu fully affirmed and praised the development of DEEPBLUE Medical. After learning about the production and operation of DEEPBUE Medical in detail and experiencing the products on site, Secretary Yu Aihua attached great importance to discussing the trial of the New Coronavirus antigen product in Hefei with relevant departments on the spot, and requested the development and reform, Departments such as economics and information technology, science and technology and other departments will send personnel to station to help enterprises carry out registration application work. Ms. Chen Fengling, general manager of DEEPBLUE Medical, expressed her heartfelt thanks to the leaders of Secretary Yu and his party for their concern and support, and said that she would actively cooperate with relevant departments to complete the submission of application materials for the domestic listing registration certificate, promote the development of local medical and health services at a higher level, and serve the current severe epidemic situation. Contribute scientific research to the situation.

Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deepblue Medical") has made great achievements in expanding the market recently. Its domestic business is booming, and its foreign trade business is constantly breaking through. In order to better serve the EU market, Deepblue Medical has been deeply engaged in the field of technology research and development. After unremitting efforts, the self-developed novel coronavirus (COVID-19) antigen detection reagent-saliva has successfully obtained the CE1434 certificate on November 10, 2021. Deepblue medical novel coronavirus (COVID-19) antigen detection reagent-saliva successfully obtained the CE1434 certificate. So far, Deepblue Medical has passed CE1434 certification for 3 types of novel coronavirus (COVID-19) products, mainly including novel coronavirus (COVID-19) neutralizing antibody (double antigen sandwich) detection reagents, novel coronavirus (COVID-19) antigen detection reagents -Anterior nose, novel coronavirus (COVID-19) antigen detection reagents-saliva, so far, Deepblue Medical is one of the only IVD companies in China that have obtained three certificates at the same time. Deepblue Medical has a wealth of novel coronavirus products and detection solutions. Help global epidemic prevention and control. Deepblue Medical Novel Coronavirus (COVID-19) Antigen Saliva Detection Reagent can quickly detect whether saliva contains nocel coronavirus through saliva samples collected from individuals. It is a very suitable product for personal and family self-testing. It has the following main features Features: Convenient sampling Convenient and fast The results are accurate Since the early stage of the outbreak of the novel coronavirus, Deepblue Medical has integrated its technical strength, and its self-developed series of novel coronavirus (COVID-19) antigen detection reagents have been verified by multiple authoritative institutions: through the British Phase 3B test, the German BfarM special authorization, the Netherlands MINVWS special authorization, etc. The CE1434 certification of the series of novel coronavirus products not only reflects that the product's excellent performance and good user experience have been fully recognized, and meets the needs of the international market, it is also a favorable evidence for Deepblue Medical's influence in the IVD industry, international customer recognition, and international competitiveness. . Deepblue Medical Novel Coronavirus (COVID-19) Antigen Detection Reagent - Saliva Detection Reagent Relying on professional scientific research and innovation strength, Deepblue Medical has independently developed novel coronavirus (COVID-19) antigen saliva detection reagents in a faster and more convenient way to meet the needs of individuals and families for self-testing, allowing more people to cut the infection chain faster , to prevent the risk of virus transmission. In addition, Deep Blue can also provide a full range of rapid detecti...

As a responsible and responsible enterprise, DEEPBLUE Medical has been actively repaying the society and continuously fulfilling its corporate citizenship responsibilities. DEEPBLUE Medical has been actively practicing corporate social responsibility for a long time, making continuous efforts in multiple dimensions, focusing on poverty alleviation, education, community, health and other directions, and integrating the core advantages and responsibilities of the enterprise into public welfare and charity. In the spring of 2020, a sudden epidemic disrupted people's lives and touched everyone's heart. Responsible enterprises and caring people from all walks of life have contributed to the prevention and control of the epidemic, and made concerted efforts with all the "guardians" who are fighting on the front line through various forms of donations to fight the epidemic. Bits of little love converge into a stream of warmth that warms people's hearts. In the fight against the epidemic, DEEPBLUE Medical continues to have caring tributaries to join in this "battle" to do their part to fight the epidemic. 1.Donate to Hong Kong On February 21, 2022, the Spring Festival was supposed to be full of flavor, but Hong Kong, China was shrouded in a severe pneumonia epidemic. Ms. Chen Fengling, general manager of DEEPBLUE Medical, actively fulfilled her social responsibilities, gathered strengths in the field to give full play to the industry's strengths, organized the company to donate 20 boxes of COVID-19 antigen front nose self-testing reagents to Hong Kong, and received them from the community in Hong Kong on March 10. Thank you letter from Anti-epidemic Connection. 2.Donate to King's College London In March 2020, DEEPBLUE Medical donated 10,000 SARS-CoV-2 (IgG/IgM) antibody detection kits to King's College London through Peking University HSBC Business School, and received a letter from Mr. Robert Lechler, Senior Vice President of King's College, UK. Thank you letter, the letter said: "One World, One Fight". DEEPBLUE Medical is proud to join hands with the United Kingdom to fight the epidemic, and is even more proud to receive a letter of thanks from Mr. Robert Lechler. 3.Donate to some schools in the province DEEPBLUE Medical donated hand sanitizer gel to Hefei High-tech Zone for use in school resumption. Donated hand sanitizer gel to the Feixi County Yandian Township Special Needs Support Center, Anhui Red Cross Fraternity School, Huangshan Jinchuan Middle School and Taihu Shahe Middle School for epidemic prevention and control. Deep Blue Medical cares about the elderly and children, and the elderly care center and school work together to fight the "epidemic". 4.Help Wuhan Epidemic Prevention and Control At the beginning of 2020, the new crown pneumonia epidemic broke out in Wuhan, Hubei Province for the first time. DEEPBLUE Medical responded quickly and started the donation process as soon as possible to make targeted donations to Wuhan Union Hospital in ...

The virus is ruthless, but there is love in the world. At present, in the tense battle of the whole people to fight against the COVID-19 epidemic, DEEPBLUE Medical donated the COVID-19 antigen detection kits, practiced its social responsibility with practical actions, reflected its mission, and helped the epidemic prevention and control work. In order to support Hefei's epidemic prevention and control work, on March 15th and 16th, DEEPBLUE Medical donated  COVID-19 antigen detection kits to the High-tech Zone Emergency Office and Luyang District Emergency Office respectively. The Municipal Red Cross Society donated 2 million copies of the COVID-19 antigen detection kits, explaining the responsibility and responsibility of enterprises with practical actions. In the current epidemic situation, fast words take the lead. In order to send the donated materials to various regions in Hefei as quickly as possible, DEEPBLUE Medical makes it play a role in the prevention and control of the epidemic. As soon as the donation ceremony is over, the deployment of donation matters will be started immediately. Efficiently complete the inventory and docking of donated products, so that each box of the COVID-19 antigen detection kits can exert the greatest value. On the evening of March 19, the staff of the Red Cross Society of Hefei came to the DEEPBLUE Medical Storage Center in Mingzhu Industrial Park to connect the distribution and transportation of reagents on site. The first batch of 430,000 the COVID-19 antigen detection kits were successively sent to Chaohu City, Lujiang County, Yaohai District, Baohe District, Shushan District and Luyang District. At 22 o'clock, the last anti-epidemic material transport vehicle left, and the friends of DEEPBLUE Medical temporarily relaxed their highly tense nerves. In the critical period of epidemic prevention and control, boxes of the COVID-19 antigen detection kits interpret the corporate responsibility and love of DEEPBLUE Medical. DEEPBLUE Medical uses practical actions to transmit positive social energy, and Hefei is more determined to win the epidemic. The battle of prevention and control has injected strong spiritual strength, fighting against the epidemic with everyone and protecting health and tranquility. In this battlefield without gunpowder smoke, DEEPBLUE Medical believes that by working together and united, we will be able to win the battle of epidemic prevention and control as soon as possible!